Tag: capital markets

Group CFO of SingularityNET Foundation since 2020, scaling the ecosystem from $40M USD market cap to multi-billion USD market cap $90M USD in digital...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, July 22, 2025 /CNW/ - First Mining...

Seasoned, Acclaimed Former Gaming and Lodging Analyst Brings 25 Years of Experience and Relationships to New Role

Seasoned, Acclaimed Former Gaming and Lodging Analyst Brings 25 Years of Experience and Relationships to New Role

Route modernization and expansion enabling greater regional accessibility Key regional and intercity corridor upgrade project commences DALLAS, July 22, 2025 /PRNewswire/ -- Jacobs (NYSE: J) has been...

JOHANNESBURG, July 22, 2025 /PRNewswire/ -- Production and sales metrics for the year ended 30 June 2025 Sasol has published its production and sales performance metrics...

TORONTO, July 21, 2025 /CNW/ - Bank of Montreal (TSX: BMO) (NYSE: BMO or the "Bank") today announced the pricing of USD 1.0 billion...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Uni-Fuels Holdings Limited (NASDAQ: UFG), (“Uni-Fuels” or the “Company”), a global provider of marine fuel solutions headquartered in Singapore, today announced that its wholly-owned subsidiary, Uni-Fuels Pte Ltd (“Uni-Fuels Singapore”), has successfully completed the Company’s first-ever commercial paper (“CP”) issuance, raising USD 3 million through ADDX, a private market platform regulated by the Monetary Authority of Singapore. The offering was oversubscribed, reflecting strong demand from accredited investors.